Target intelligence / Profile preview

Sprouty RTK signaling antagonist 1 (SPRY1)

Target: SPRY1
Molecular classification: Other (negative regulator of receptor tyrosine kinase signaling), Negative regulator of FGF signaling, Intracellular signaling modulator

Overview

Sprouty RTK signaling antagonist 1 (SPRY1) is a cytoplasmic protein best known as a negative regulator of receptor tyrosine kinase (RTK) signaling, particularly pathways initiated by fibroblast growth factors (FGFs) and other growth factors. SPRY1 inhibits downstream signaling (including MAPK/ERK phosphorylation), thereby controlling cell proliferation, migration, and fate. It functions as part of a negative feedback loop in various tissues to modulate growth factor responses. SPRY1 plays critical roles in embryonic development and differentiation, acting in organogenesis (e.g., kidney, brain, cranio

Other names: Protein sprouty homolog 1Spry-1hSPRY1Sprouty, Drosophila, homolog of, 1 (antagonist of FGF signaling)Sprouty homolog 1, antagonist of FGF signalingSprouty (Drosophila) homolog 1 (antagonist of FGF signaling)Sprouty homolog 1

Mechanism of action

Antagonism of growth factor receptor signaling (particularly FGF receptor pathway) Inhibition of MAPK/ERK phosphorylation

Biological functions

Signal transductionNegative regulation of receptor tyrosine kinase signalingCell proliferationCell differentiationCell migrationApoptosisEmbryonic developmentImmune and inflammatory response modulation

Disease associations

CancerDevelopmental disorders (e.g., kidney, brain, and craniofacial abnormalities)InflammationRenal hypodysplasia/aplasiaOther (potential tumor suppressor and involvement in epithelial–mesenchymal transition)

Safety considerations

Altering SPRY1 activity could impact proliferation, apoptosis, and tissue development, raising potential concern for off-target effects on normal tissue homeostasis, tumor suppression, and organogenesis[1]

Interacting drugs

None established or clinically approved as of this compilation

Biomarkers

SPRY1 expression as a prognostic marker in certain cancers (e.g., breast, prostate, liver, lung, thyroid)[1][2]SPRY1 levels in developmental and renal disorders

Beyond the preview

Go deeper on Sprouty RTK signaling antagonist 1 (SPRY1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sprouty RTK signaling antagonist 1 (SPRY1).

Explore the full profile